Preclinical evaluation of stereopure antisense oligonucleotides for allele-selective lowering of mutant HTT
Naoki Iwamoto,Yuanjing Liu,Maria Frank-Kamenetsky,Abbie Maguire,Wei Chou Tseng,Kristin Taborn,Nayantara Kothari,Ali Akhtar,Keith Bowman,Juili Dilip Shelke,Anthony Lamattina,Xiao Shelley Hu,Hyun Gyung Jang,Pachamuthu Kandasamy,Fangjun Liu,Ken Longo,Richard Looby,Meena,Jake Metterville,Qianli Pan,Erin Purcell-Estabrook,Mamoru Shimizu,Priyanka Shiva Prakasha,Stephany Standley,Hansini Upadhyay,Hailin Yang,Yuan Yin,Anderson Zhao,Christopher Francis,Mike Byrne,Elena Dale,Gregory L Verdine,Chandra Vargeese
DOI: https://doi.org/10.1016/j.omtn.2024.102246
2024-06-11
Abstract:Huntington's disease (HD) is an autosomal dominant disease caused by the expansion of cytosine-adenine-guanine (CAG) repeats in one copy of the HTT gene (mutant HTT, mHTT). The unaffected HTT gene encodes wild-type HTT (wtHTT) protein, which supports processes important for the health and function of the central nervous system. Selective lowering of mHTT for the treatment of HD may provide a benefit over nonselective HTT-lowering approaches, as it aims to preserve the beneficial activities of wtHTT. Targeting a heterozygous single-nucleotide polymorphism (SNP) where the targeted variant is on the mHTT gene is one strategy for achieving allele-selective activity. Herein, we investigated whether stereopure phosphorothioate (PS)- and phosphoryl guanidine (PN)-containing oligonucleotides can direct allele-selective mHTT lowering by targeting rs362273 (SNP3). We demonstrate that our SNP3-targeting molecules are potent, durable, and selective for mHTT in vitro and in vivo in mouse models. Through comparisons with a surrogate for the nonselective investigational compound tominersen, we also demonstrate that allele-selective molecules display equivalent potency toward mHTT with improved durability while sparing wtHTT. Our preclinical findings support the advancement of WVE-003, an investigational allele-selective compound currently in clinical testing (NCT05032196) for the treatment of patients with HD.